

## ALKEM LABORATORIES LTD.

Regd. Office: "ALKEM HOUSE", Senapati Bapat Marg,

Lower Parel, Mumbai - 400 013. Phone: 022-3982 9999, Fax: 022-2495 2955

Email: contact@alkem.com Website: www.alkemlabs.com

CIN :- L00305MH1973PLC174201



10th October, 2017

The Corporate Relationship Department

**BSE** Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai 400 001.

Scrip Code: 539523

National Stock Exchange of India Limited

Exchange Plaza,

Bandra Kurla Complex,

Bandra East,

Mumbai 400 051.

Scrip Symbol: ALKEM

Dear Sirs,

Sub: Statement of Investor Grievances for the quarter ended 30th September, 2017

In terms of Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Statement of Investor Grievances for the quarter ended 30<sup>th</sup> September, 2017.

Kindly take the same on record.

Sincerely,

For Alkem Laboratories Limited

Manish Narang

NO.VO 0

President - Legal, Company Secretary & Compliance Officer

Encl: a/a



## ALKEM LABORATORIES LTD.

Regd. Office: "ALKEM HOUSE", Senapati Bapat Marg,

Lower Parel, Mumbai - 400 013. Phone: 022-3982 9999, Fax: 022-2495 2955

Email: contact@alkem.com Website: www.alkemlabs.com

CIN: - L00305MH1973PLC174201



## STATEMENT OF INVESTOR GRIEVANCES FOR THE QUARTER ENDED $30^{\rm TH}$ SEPTEMBER, 2017

[Pursuant to Regulation 13(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015]

On the basis of information provided by the Registrar and Share Transfer Agent and further information available with the Company, following are the details of investor grievances for the quarter ended 30<sup>th</sup> September, 2017.

Particulars	Number of Investor Complaints
Pending at the beginning of the quarter	0
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	0

For Alkem Laboratories Limited

**Manish Narang** 

President - Legal, Company Secretary & Compliance Officer

Date: 10th October, 2017

Place: Mumbai